GTx, Inc. (GTXI) Files An 8-K Other Events
Item 8.01 Other Events.
On November16, 2016, GTx,Inc. issued a press release announcing
the achievement of the Stage 1 milestone for the 18 mg cohort of
its Phase 2 clinical trial of enobosarm (GTx-024) to treat women
with advanced, estrogen receptor positive, androgen receptor
positive breast cancer.
A copy of the press release is furnished as Exhibit99.1 to this
Current Report.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued by GTx,Inc. dated November16, 2016 |
About GTx, Inc. (GTXI)
